Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for May 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Antiretroviral Therapy Greatly Cuts HIV Partner Transmission
THURSDAY, May 27 (HealthDay News) -- In heterosexual HIV-1 patients, antiretroviral therapy (ART) can reduce the risk of HIV transmission to sexual partners by 92 percent, according to research published online May 27 in The Lancet.
Low Phosphorus Linked to Early Death in HIV Therapy
MONDAY, May 24 (HealthDay News) -- Low blood phosphorus levels are associated with high death rates among HIV-infected patients beginning antiretroviral therapy (ART) in sub-Saharan Africa, according to a study published online May 18 in PLoS ONE.
Many General Internists Leave Field by Mid-Career
FRIDAY, May 14 (HealthDay News) -- Roughly one out of six general internists are leaving internal medicine by mid-career, a substantially higher proportion compared to internal medicine subspecialists, according to survey results published April 29 in the Journal of General Internal Medicine.
New FDA Program Targets Misleading Drug Advertising
WEDNESDAY, May 12 (HealthDay News) -- The U.S. Food and Drug Administration has announced the launch of a new program to educate health care providers regarding their role in making certain that advertisements and promotions for prescription drugs are truthful and not misleading.
Copyright © 2010 ScoutNews, LLC. All rights reserved.
|Previous: May 2010 Briefing - Gastroenterology||Next: May 2010 Briefing - Infectious Disease|
Reader comments on this article are listed below. Review our comments policy.